Open an account Help & support Register Account summary Log out
Skip Header
Home Stock market news

Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

TSB appoints Marc Armengol as new CEO

Fri 29 Nov 2024 14:04

(Sharecast News) - TSB said on Friday that it has appointed Marc Armengol as its new chief executive officer. Armengol will succeed Robin Bulloch, who will retire after a 45-year career in retail banking, including five years at TSB, which is owned by Banco Sabadell.

Armengol has served as strategy director at TSB and a member of the Executive Committee, from 2018 to 2021, and has been a member of the TSB board since 2022. He joined Sabadell in 2002 and TSB said he has "extensive" international experience, including several years as COO in their international businesses.

He is expected to rejoin the bank in early 2025 and will work with Bulloch on an orderly handover.

TSB chair Nick Prettejohn said: "We're grateful to Robin for his outstanding contribution not only to TSB but also to retail banking for more than four decades. Robin leaves TSB a successful, simpler, stronger and more customer-focused bank and we're well positioned for the next phase of growth.

"He hands over the baton to Marc who is a proven leader and knows TSB well. As an established TSB Board member, I've always admired Marc's ambition for the future of TSB and its customers. Marc's appointment will allow us to build further on the progress of recent years."

Share this article

Related Sharecast Articles

Fri 17 Jul 2026 15:20
Thalia Therapeutics enters new phase of development
(Sharecast News) - Thalia Therapeutics said on Friday that it was entering a new phase of development ahead of its annual general meeting, with the proposed acquisition of Sanmirna Therapeutics and an oversubscribed £2.75m fundraising expected to accelerate its transition into a clinical-stage RNA therapeutics company.
Fri 17 Jul 2026 15:18
Metir inks water system deal with Portsmouth Aviation
(Sharecast News) - Metir announced Friday that it has signed a memorandum of understanding with Portsmouth Aviation to evaluate integrated water treatment and monitoring systems combining Portsmouth's PaquaVida purification platform with Metir's Modern Water Microtox biological monitoring technology.
Fri 17 Jul 2026 12:51
System1 reiterates rejection of Brave Bison's revised offer
(Sharecast News) - System1 reiterated its unanimous rejection of Brave Bison's revised cash-and-share proposal on Friday, saying feedback from major shareholders supported the board's view that the offer materially undervalued the company.
Fri 17 Jul 2026 12:40
ConocoPhillips to buy 42% stake in BP Iraq oil fields
(Sharecast News) - BP said on Friday that it has agreed terms for ConocoPhillips to buy a 42% interest in BP Energy Company of Kirkuk (BP ECKL).

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Policies and important information
 

Accessibility | Conflicts of interest statement | Consumer Duty Target Market | Consumer Duty Value Assessment Statement | Cookie policy | Diversity, Equity & Inclusion | Diversity, Equity & Inclusion Reports | Doing Business with Fidelity | Investing in Fidelity funds | Legal information | Modern slavery | Mutual respect policy | Privacy statement | Remuneration policy | Staying secure | Statutory and Regulatory disclosures | Whistleblowing programme

 

Please remember that past performance is not necessarily a guide to future performance, the performance of investments is not guaranteed, and the value of your investments can go down as well as up, so you may get back less than you invest. When investments have particular tax features, these will depend on your personal circumstances and tax rules may change in the future. This website does not contain any personal recommendations for a particular course of action, service or product. You should regularly review your investment objectives and choices and, if you are unsure whether an investment is suitable for you, you should contact an authorised financial adviser. Before opening an account, please read the ‘Doing Business with Fidelity’ document which incorporates our client terms. Prior to investing into a fund, please read the relevant key information document or Product Summary document which contains important information about the fund.

This website is issued by Financial Administration Services Limited, which is authorised and regulated by the Financial Conduct Authority (FCA) (FCA Register number 122169) and registered in England and Wales under company number 1629709 whose registered address is Beech Gate, Millfield Lane, Lower Kingswood, Tadworth, Surrey, KT20 6RP.

© FIL Limited 2026